Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Nephrol Dial Transplant. 2011 May;26(5):1670-7. doi: 10.1093/ndt/gfq561. Epub 2010 Sep 14.
The UK national policy promotes expansion of home haemodialysis, but there are no recent data on characteristics and outcomes of a national home haemodialysis population.
We compared incident home haemodialysis patients in England and Wales (n = 225, 1997-2005) with age- and sex-matched incident peritoneal dialysis, hospital haemodialysis and satellite haemodialysis patients with follow-up until 31 December 2006. Cox regression analyses included time-dependent changes of wait-listing for transplantation (a proxy for health status), start of home haemodialysis and transplantation.
There was a median delay of 12 months between starting renal replacement therapy (RRT) and home haemodialysis. During that first year of RRT, > 50% of home haemodialysis patients were wait-listed for kidney transplantation; hospital haemodialysis patients had a lower rate of wait-listing over time [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.44-0.70; P < 0.001]. In crude analyses, there was a marked survival advantage of home haemodialysis patients compared with other modalities (log-rank P-value < 0.001). In adjusted analyses, being on home haemodialysis yielded a long-term survival benefit compared with peritoneal dialysis (HR 0.61, 95% CI 0.40-0.93), and a borderline advantage compared with hospital haemodialysis (HR 0.68, 95% CI 0.44-1.03). There was no evidence of an advantage compared with satellite haemodialysis (HR 0.94, 95% CI 0.65-1.37).
Home haemodialysis patients have better survival compared with other dialysis modalities. Some of this crude survival advantage is due to selection of a healthier patient cohort as evidenced by higher transplant wait-listing rates. The advantage over peritoneal dialysis persisted after adjustment for wait-listing and transplantation over time.
英国国家政策提倡扩大居家血液透析,但目前尚无全国居家血液透析患者特征和结局的最新数据。
我们比较了英格兰和威尔士的 225 例起始居家血液透析患者(1997-2005 年)与年龄和性别匹配的起始腹膜透析、住院血液透析和卫星血液透析患者,随访至 2006 年 12 月 31 日。Cox 回归分析包括移植等待时间(健康状况的替代指标)、起始居家血液透析和移植的时间依赖性变化。
开始肾脏替代治疗(RRT)和起始居家血液透析之间存在 12 个月的中位延迟。在 RRT 的最初 1 年内,超过 50%的居家血液透析患者等待肾脏移植;住院血液透析患者的等待移植率随时间呈下降趋势[风险比(HR)0.56,95%置信区间(CI)0.44-0.70;P<0.001]。在未经调整的分析中,与其他模式相比,居家血液透析患者具有显著的生存优势(对数秩检验 P 值<0.001)。在调整后的分析中,与腹膜透析相比,居家血液透析具有长期生存优势(HR 0.61,95%CI 0.40-0.93),与住院血液透析相比具有边缘优势(HR 0.68,95%CI 0.44-1.03)。与卫星血液透析相比,没有证据表明具有优势(HR 0.94,95%CI 0.65-1.37)。
与其他透析模式相比,居家血液透析患者的生存率更高。这种粗生存率优势的部分原因是选择了更健康的患者队列,证据是更高的移植等待列表率。在随着时间推移调整移植等待和移植后,这种优势仍然存在。